GeneOne Life Science, Inc. (KRX:011000)
2,020.00
-20.00 (-0.98%)
At close: Mar 28, 2025, 3:30 PM KST
GeneOne Life Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Net Income | -48,537 | -77,768 | -38,150 | -15,888 | -18,648 | Upgrade
|
Depreciation & Amortization | 17,961 | 12,776 | 5,424 | 4,650 | 4,021 | Upgrade
|
Loss (Gain) From Sale of Assets | -2.82 | -3.4 | -1.31 | 106.64 | - | Upgrade
|
Asset Writedown & Restructuring Costs | - | 32,309 | - | - | - | Upgrade
|
Loss (Gain) From Sale of Investments | 4.25 | - | - | - | - | Upgrade
|
Provision & Write-off of Bad Debts | 2.7 | -845.52 | 1,293 | 111.17 | -174.13 | Upgrade
|
Other Operating Activities | 8,442 | 3,171 | 3,579 | -2,084 | 1,219 | Upgrade
|
Change in Accounts Receivable | 407.86 | 4,835 | -2,848 | 68.06 | 1,672 | Upgrade
|
Change in Inventory | -2,096 | -207.63 | -4,256 | -2,415 | 409.55 | Upgrade
|
Change in Accounts Payable | 10,240 | 3,801 | -10,003 | 10,610 | 4,529 | Upgrade
|
Change in Income Taxes | - | - | - | -97.74 | -67.04 | Upgrade
|
Change in Other Net Operating Assets | -1,987 | 188.33 | 20,850 | -194.83 | -8,908 | Upgrade
|
Operating Cash Flow | -16,058 | -21,744 | -24,113 | -4,849 | -15,916 | Upgrade
|
Capital Expenditures | -3,298 | -5,601 | -45,306 | -82,442 | -16,153 | Upgrade
|
Sale of Property, Plant & Equipment | 2.12 | 15.7 | - | 29.13 | - | Upgrade
|
Sale (Purchase) of Intangibles | -69.14 | -51.59 | -101.81 | -75.24 | -216.6 | Upgrade
|
Investment in Securities | 470.79 | 31,529 | 53,000 | -57,000 | -27,536 | Upgrade
|
Other Investing Activities | 46 | -0 | -151.33 | -5,961 | - | Upgrade
|
Investing Cash Flow | -2,845 | 25,892 | 8,055 | -146,398 | -44,305 | Upgrade
|
Short-Term Debt Issued | 1,352 | 3,792 | 701.15 | 1,054 | - | Upgrade
|
Long-Term Debt Issued | 9,224 | 6,271 | 11,469 | - | 23,520 | Upgrade
|
Total Debt Issued | 10,576 | 10,063 | 12,171 | 1,054 | 23,520 | Upgrade
|
Short-Term Debt Repaid | -506.85 | -2,100 | - | -150.86 | -958.08 | Upgrade
|
Long-Term Debt Repaid | -2,700 | -18,712 | -5,537 | -1,639 | -10,731 | Upgrade
|
Total Debt Repaid | -3,207 | -20,812 | -5,537 | -1,790 | -11,689 | Upgrade
|
Net Debt Issued (Repaid) | 7,369 | -10,749 | 6,633 | -735.35 | 11,831 | Upgrade
|
Issuance of Common Stock | 3,590 | 2,470 | 382.44 | 112,609 | 94,404 | Upgrade
|
Other Financing Activities | -0 | -5.64 | -2.97 | -849.86 | - | Upgrade
|
Financing Cash Flow | 10,959 | -8,285 | 7,013 | 111,023 | 106,235 | Upgrade
|
Foreign Exchange Rate Adjustments | 13.81 | -13.29 | -3.42 | 101.37 | -503.35 | Upgrade
|
Miscellaneous Cash Flow Adjustments | 0 | - | 0 | 0 | 0 | Upgrade
|
Net Cash Flow | -7,931 | -4,150 | -9,049 | -40,122 | 45,510 | Upgrade
|
Free Cash Flow | -19,356 | -27,345 | -69,419 | -87,291 | -32,069 | Upgrade
|
Free Cash Flow Margin | -54.19% | -68.02% | -142.49% | -225.56% | -77.27% | Upgrade
|
Free Cash Flow Per Share | -243.66 | -351.62 | -895.90 | -1175.77 | -531.20 | Upgrade
|
Cash Interest Paid | 74.66 | 82.15 | 58.5 | - | 48.96 | Upgrade
|
Cash Income Tax Paid | -236.05 | 104.9 | 326.55 | 189.71 | - | Upgrade
|
Levered Free Cash Flow | 2,211 | -22,581 | -73,691 | -103,116 | -13,891 | Upgrade
|
Unlevered Free Cash Flow | 3,558 | -21,843 | -69,123 | -100,332 | -13,498 | Upgrade
|
Change in Net Working Capital | -15,863 | -1,263 | 4,014 | 5,259 | -10,432 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.